BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 16865362)

  • 1. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
    Stephan D; Winkler M; Kühner P; Russ U; Quast U
    Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
    Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
    J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
    Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
    Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.
    Kühner P; Prager R; Stephan D; Russ U; Winkler M; Ortiz D; Bryan J; Quast U
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar; 385(3):299-311. PubMed ID: 22083559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
    Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
    Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
    Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
    Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.
    Russ U; Hambrock A; Artunc F; Löffler-Walz C; Horio Y; Kurachi Y; Quast U
    Mol Pharmacol; 1999 Nov; 56(5):955-61. PubMed ID: 10531400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
    Gribble FM; Tucker SJ; Seino S; Ashcroft FM
    Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells.
    Gromada J; Dissing S; Kofod H; Frøkjaer-Jensen J
    Diabetologia; 1995 Sep; 38(9):1025-32. PubMed ID: 8591815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide and related hypoglycemic benzoic acid derivatives.
    Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
    J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
    Hambrock A; Löffler-Walz C; Russ U; Lange U; Quast U
    Mol Pharmacol; 2001 Jul; 60(1):190-9. PubMed ID: 11408614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.
    Lim JG; Lee HY; Yun JE; Kim SP; Park JW; Suh SI; Jang BC; Cho CH; Bae JH; Kim SS; Han J; Park MJ; Song DK
    Biochem Pharmacol; 2004 Sep; 68(5):901-10. PubMed ID: 15294453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis and characteristics of KATP channel in human corporal smooth muscle cells.
    Insuk SO; Chae MR; Choi JW; Yang DK; Sim JH; Lee SW
    Int J Impot Res; 2003 Aug; 15(4):258-66. PubMed ID: 12934053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide.
    Russ U; Lange U; Löffler-Walz C; Hambrock A; Quast U
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1049-55. PubMed ID: 11714894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S67-80. PubMed ID: 8529521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
    Cui Y; Tinker A; Clapp LH
    Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T).
    Hambrock A; de Oliveira Franz CB; Hiller S; Osswald H
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1031-7. PubMed ID: 16306272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells.
    Mukai E; Ishida H; Kato S; Tsuura Y; Fujimoto S; Ishida-Takahashi A; Horie M; Tsuda K; Seino Y
    Am J Physiol; 1998 Jan; 274(1):E38-44. PubMed ID: 9458745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts.
    Weyermann A; Vollert H; Busch AE; Bleich M; Gögelein H
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):374-81. PubMed ID: 15024553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.